GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Provexis PLC (LSE:PXS) » Definitions » Revenue

Provexis (LSE:PXS) Revenue : £0.60 Mil (TTM As of Sep. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Provexis Revenue?

Provexis's revenue for the six months ended in Sep. 2023 was £0.39 Mil. Its revenue for the trailing twelve months (TTM) ended in Sep. 2023 was £0.60 Mil. Provexis's Revenue per Share for the six months ended in Sep. 2023 was £0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was £0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.


Provexis Revenue Historical Data

The historical data trend for Provexis's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Provexis Revenue Chart

Provexis Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.32 0.35 0.51 0.43 0.39

Provexis Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 0.22 0.18 0.21 0.39

Competitive Comparison of Provexis's Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Provexis's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Provexis's Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Provexis's Revenue distribution charts can be found below:

* The bar in red indicates where Provexis's Revenue falls into.



Provexis Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.60 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Provexis  (LSE:PXS) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Provexis Revenue Related Terms

Thank you for viewing the detailed overview of Provexis's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Provexis (LSE:PXS) Business Description

Traded in Other Exchanges
Address
2 Blagrave Street, I Ford, Reading, Berkshire, GBR, RG1 1AZ
Provexis PLC is a British food company. It is engaged in developing and licensing the Fruitflow, which is a patented, natural, breakthrough ingredient which helps with platelet aggregation. Fruitflow reduces the propensity for aberrant blood clotting, typically associated with cardiovascular disease, which can result in heart attack and stroke. The extract is available in two formats, a syrup and a powder, and it can be included in a broad range of food, beverage and dietary supplement formats.

Provexis (LSE:PXS) Headlines

From GuruFocus

Pyxis Tankers Inc. - Significant Improvement of Charter Rates Boosts Revenue Expectations

By Stock market mentor Stock market mentor 01-27-2023